Business Standard

Jubilant Life slips 17% in 3 days on weak Q1 results, CFO's resignation

The management said the company is witnessing strong demand conditions and improved pricing environment

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Premium

According to virologists, there are four phases to developing a vaccine.

SI Reporter Mumbai
Shares of Jubilant Life Sciences declined for the third straight day, down 8 per cent to Rs 686 on the BSE on Wednesday after reporting weak earnings for the quarter ended June 2020 (Q1FY21).

The pharmaceutical company also informed that Alok Vaish, Chief Financial Officer (CFO) and Key Managerial Personnel, has tendered his resignation from services of the Company which has been accepted by the Company. He shall continue in his current role until September 11, 2020.

In the past three trading days, the stock has declined 17 per cent, as compared to 0.78 per cent decline in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in